{"id":"ab-106","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"AB-106 targets the TGF-β pathway, which plays a critical role in immune suppression and tissue fibrosis in various disease states. By inhibiting TGF-β receptor signaling, the drug aims to enhance anti-tumor immunity and reduce pathological fibrotic responses. This mechanism is being explored in oncology and potentially fibrotic disease indications.","oneSentence":"AB-106 is a TGF-β receptor inhibitor that blocks transforming growth factor-beta signaling to modulate immune responses and reduce fibrosis.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T02:28:08.388Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced solid tumors (Phase 2 development)"}]},"trialDetails":[{"nctId":"NCT07154706","phase":"PHASE3","title":"Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)","status":"RECRUITING","sponsor":"Nuvation Bio Inc.","startDate":"2025-08-21","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":180},{"nctId":"NCT04395677","phase":"PHASE2","title":"A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nuvation Bio Inc.","startDate":"2020-07-07","conditions":"Non Small Cell Lung Cancer","enrollment":173},{"nctId":"NCT04617054","phase":"PHASE2","title":"Phase II Study of AB-106 to Treat Patients With Solid Tumors With NTRK Gene Fusion","status":"TERMINATED","sponsor":"Nuvation Bio Inc.","startDate":"2021-06-01","conditions":"Solid Tumor","enrollment":14},{"nctId":"NCT04919811","phase":"PHASE2","title":"Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nuvation Bio Inc.","startDate":"2021-09-01","conditions":"Non Small Cell Lung Cancer","enrollment":217},{"nctId":"NCT06841874","phase":"","title":"Expanded Access Program of Taletrectinib in Patients With Advanced or Metastatic ROS1-Positive NSCLC","status":"NO_LONGER_AVAILABLE","sponsor":"Nuvation Bio Inc.","startDate":"","conditions":"Lung Neoplasms, Respiratory Tract Neoplasms, Thoracic Neoplasms","enrollment":""},{"nctId":"NCT07199010","phase":"","title":"Real-world Study of Taletrectinib in Advanced ROS1+ NSCLC Following Entrectinib Progression","status":"NOT_YET_RECRUITING","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2025-10","conditions":"Non-small Lung Cancer","enrollment":50},{"nctId":"NCT07008287","phase":"","title":"Real-world Study of Taletrectinib for Advanced ROS1+ NSCLC With Brain Metastases","status":"RECRUITING","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2025-06-04","conditions":"Non-Small Cell Lung Cancer","enrollment":100},{"nctId":"NCT06214793","phase":"PHASE2","title":"Taletrectinib in Previously Treated Metastatic CDH1-mutated Invasive Lobular Cancer (ILC)","status":"SUSPENDED","sponsor":"Megan Kruse, MD","startDate":"2026-04","conditions":"Breast Cancer, Metastatic Breast Cancer","enrollment":61},{"nctId":"NCT05357820","phase":"PHASE1","title":"A Study of AB-106 in Chinese Healthy Adult Men Evaluated the Effects of Itraconazole and Rifampicin on AB-106 PK","status":"COMPLETED","sponsor":"Nuvation Bio Inc.","startDate":"2021-07-19","conditions":"Solid Tumor","enrollment":56},{"nctId":"NCT05609929","phase":"PHASE1","title":"Study the Effect of Omeprazole on AB-106 Pharmacokinetics","status":"COMPLETED","sponsor":"Nuvation Bio Inc.","startDate":"2022-11-02","conditions":"Pharmacokinetic Study","enrollment":24},{"nctId":"NCT05357911","phase":"PHASE1","title":"A Study on the Effect of AB-106 on the Pharmacokinetics of Digoxin","status":"COMPLETED","sponsor":"Nuvation Bio Inc.","startDate":"2021-07-13","conditions":"Solid Tumor","enrollment":16}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["DS-6051b"],"phase":"phase_2","status":"active","brandName":"AB-106","genericName":"AB-106","companyName":"Nuvation Bio Inc.","companyId":"nuvation-bio-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AB-106 is a TGF-β receptor inhibitor that blocks transforming growth factor-beta signaling to modulate immune responses and reduce fibrosis. Used for Advanced solid tumors (Phase 2 development).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}